



March 25, 2014

MediWound Announces Closing of Initial Public Offering

YAVNE, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of \$14.00 per share. All of the shares of common stock in the offering were offered by MediWound and include 750,000 shares issued pursuant to the full exercise of the underwriters' 30-day option to purchase up to 750,000 additional shares at the initial public offering price.

Credit Suisse Securities (USA) LLC, Jefferies LLC and BMO Capital Markets Corp. acted as book-running managers for the offering. Oppenheimer & Co. is acting as co-manager. Rothschild, Inc. served as financial advisor to MediWound on the transaction.

The offering of these securities was made by means of a written prospectus. A copy of the prospectus related to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by phone (800) 221-1037 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022 or by telephone at 877-547-6340.

A registration statement relating to the initial public offering has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

Contacts:

Sharon Malka
CFO
MediWound
ir@mediwound.co.il

Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com

Source: MediWound

News Provided by Acquire Media